Immunology latest news
The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA® showed highly statistically significant rates of endoscopic remission at one year in the pivotal QUASAR program1,2,3,4,5
TREMFYA® is now approved for the treatment of plaque psoriasis, active psoriatic arthritis and ulcerative colitis
TREMFYA® is now approved for the treatment of plaque psoriasis, active psoriatic arthritis and ulcerative colitis
NM26 is a Phase 2-ready, first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD)
The Company is leveraging a multi-pathway approach to transform treatment in atopic dermatitis and other immune-mediated diseases
The Company is leveraging a multi-pathway approach to transform treatment in atopic dermatitis and other immune-mediated diseases
First-and-only FcRn blocker to demonstrate superiority in activities of daily living (MG-ADLa) over placebo when added to standard of care over 24 weeks in antibody positive patients: anti-AChR+, anti-MuSK+, anti-LRP4+
The Phase 3 AZALEA and Phase 3 FREESIA clinical studies are enrolling pregnant individuals who are at risk for severe HDFN and FNAIT
These rare and potentially life-threatening alloantibody diseases affecting pregnant individuals and their fetus or newborn currently have no approved treatments
These rare and potentially life-threatening alloantibody diseases affecting pregnant individuals and their fetus or newborn currently have no approved treatments
Submission is supported by 48-week results from the Phase 3 GALAXI and GRAVITI programs
TREMFYA® is the only IL-23 inhibitor to demonstrate strong endoscopic outcomes with subcutaneous (SC) induction, consistent with intravenous (IV) induction, and has the potential to be the first in its class to offer the option of both SC and IV induction therapy in Crohn’s disease
GALAXI includes data demonstrating superior outcomes for TREMFYA® versus STELARA® (ustekinumab) in Crohn’s disease
TREMFYA® is the only IL-23 inhibitor to demonstrate strong endoscopic outcomes with subcutaneous (SC) induction, consistent with intravenous (IV) induction, and has the potential to be the first in its class to offer the option of both SC and IV induction therapy in Crohn’s disease
GALAXI includes data demonstrating superior outcomes for TREMFYA® versus STELARA® (ustekinumab) in Crohn’s disease
TREMFYA® Phase 3 Crohn’s disease study achieves all primary and secondary endpoints
Patients who received nipocalimab 15 mg/kg demonstrated a greater than 70 percent relative average improvement on the primary endpoint compared to patients who received placebo
Sjögren’s disease is a chronic, debilitating, and prevalent autoantibody disease with no approved advanced treatments
Sjögren’s disease is a chronic, debilitating, and prevalent autoantibody disease with no approved advanced treatments
30 abstracts highlight the company’s robust portfolio and commitment to improving outcomes for patients with immune-mediated diseases
Features positive results from a Phase 2 study of nipocalimab in Sjögren’s disease as a late-breaking oral presentation
Features positive results from a Phase 2 study of nipocalimab in Sjögren’s disease as a late-breaking oral presentation
The Company1 enters agreement with Numab Therapeutics to acquire its wholly owned subsidiary2 for the global rights to NM26, a Phase 2-ready investigational, first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD)
NM26 has the potential to offer distinctive benefits versus existing treatments and address key unmet needs for AD patientsJ
ohnson & Johnson is committed to developing differentiated bispecific antibodies for treating AD and other immune-mediated diseases
NM26 has the potential to offer distinctive benefits versus existing treatments and address key unmet needs for AD patientsJ
ohnson & Johnson is committed to developing differentiated bispecific antibodies for treating AD and other immune-mediated diseases